anti SARS-CoV-2 equine hyperimmune serum

Anti SARS-CoV-2 equine hyperimmune serum is a biologic product consisting of highly purified polyclonal antibodies derived from the plasma of horses that have been immunized with recombinant proteins or inactivated antigens from the SARS-CoV-2 virus. The preparation typically involves enzymatic digestion to produce F(ab′)₂ antibody fragments, which retain neutralizing activity but lack the Fc region to reduce adverse reactions. These antibodies target multiple epitopes on viral proteins—most commonly the spike protein and its receptor-binding domain (RBD)—and neutralize diverse variants of concern by blocking viral entry into host cells via inhibition of spike protein binding to ACE2 receptors. The therapy is intended for passive immunization or treatment of moderate to severe COVID-19 and has demonstrated high potency in vitro and in animal models as well as clinical improvement in hospitalized patients[1][3][4][5][6].

Brand names

INOSARS

Other names

anti-SARS-CoV-2 equine immunoglobulin fragmentsanti-SARS-CoV2 equine immunoglobulin fragmentsanti-SARS-CoV 2 equine immunoglobulin fragmentsanti-SARS-CoV-2 equine F(ab′)2 immunoglobulinECIG (Equine Anti-SARS-CoV-2 Serum)equine polyclonal F(ab′)2 fragments against SARS-CoV-2therapeutic equine hyperimmune antibodies